EU regulator may approve Merck’s Covid19 pill ‘within weeks’

EU regulator may approve Merck's Covid19 pill 'within weeks'

EU regulator may approve Merck’s Covid19 pill ‘within weeks’

The European Medicines Agency said Tuesday it may decide “within weeks” whether to approve Merck’s anti-Covid pill, Lagevrio (molnupiravir), which could offer patients an easy at-home treatment for the disease.

Last week, the EMA issued emergency advice saying that molnupiravir could be used to treat adults infected with the coronavirus who don’t yet need extra oxygen and are at increased risk of developing severe disease. It is intended to be taken twice a day for five days.

Molnupiravir is also pending review with regulators in the U.S., which is expected to convene an expert panel later this month to consider authorisation.

Even if the pill is licensed, the initial supplies will be limited. Merck mentioned that it can only produce 10 million treatment courses this year. Majority of the apply has already been purchased by the governments worldwide.